Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay

Narayanan, Anoop, Narwal, Manju, Majowicz, Sydney A., Varricchio, Carmine ORCID: https://orcid.org/0000-0002-1673-4768, Toner, Shay A., Ballatore, Carlo, Brancale, Andrea ORCID: https://orcid.org/0000-0002-9728-3419, Murakami, Katsuhiko S. and Jose, Joyce 2022. Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. Communications Biology 5 (1) , 169. 10.1038/s42003-022-03090-9

[thumbnail of Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay.pdf]
Preview
PDF - Published Version
Available under License Creative Commons Attribution.

Download (7MB) | Preview

Abstract

SARS-CoV-2 proteases Mpro and PLpro are promising targets for antiviral drug development. In this study, we present an antiviral screening strategy involving a novel in-cell protease assay, antiviral and biochemical activity assessments, as well as structural determinations for rapid identification of protease inhibitors with low cytotoxicity. We identified eight compounds with anti-SARS-CoV-2 activity from a library of 64 repurposed drugs and modeled at protease active sites by in silico docking. We demonstrate that Sitagliptin and Daclatasvir inhibit PLpro, and MG-101, Lycorine HCl, and Nelfinavir mesylate inhibit Mpro of SARS-CoV-2. The X-ray crystal structure of Mpro in complex with MG-101 shows a covalent bond formation between the inhibitor and the active site Cys145 residue indicating its mechanism of inhibition is by blocking the substrate binding at the active site. Thus, we provide methods for rapid and effective screening and development of inhibitors for blocking virus polyprotein processing as SARS-CoV-2 antivirals. Additionally, we show that the combined inhibition of Mpro and PLpro is more effective in inhibiting SARS-CoV-2 and the delta variant.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Pharmacy
Additional Information: This article is licensed under a Creative Commons Attribution 4.0 International License
Publisher: Nature Research
ISSN: 2399-3642
Date of First Compliant Deposit: 16 March 2022
Date of Acceptance: 2 February 2022
Last Modified: 06 Jan 2024 05:09
URI: https://orca.cardiff.ac.uk/id/eprint/148427

Citation Data

Cited 28 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics